Previous close | 10.00 |
Open | 9.97 |
Bid | 10.33 x 100 |
Ask | 10.49 x 100 |
Day's range | 9.80 - 10.58 |
52-week range | 1.81 - 15.05 |
Volume | |
Avg. volume | 260,047 |
Market cap | 394.509M |
Beta (5Y monthly) | 1.94 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.
Solid Biosciences is shrugging off several messy years in gene therapy development. The biotech stock has gotten a triple-digit boost.
In this article, we will take a detailed look at 14 Stocks With Heavy Insider Buying In 2024. For a quick overview of such stocks, read our article 5 Stocks With Heavy Insider Buying In 2024. Markets await latest inflation numbers and the debate regarding soft vs hard landing is expected to persist in the Wall Street for months […]